Advertisement
Advertisement
U.S. markets close in 47 minutes
Advertisement
Advertisement
Advertisement
Advertisement

QuidelOrtho Corporation (QDEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
71.54-0.09 (-0.13%)
As of 03:13PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close71.63
Open71.14
Bid71.53 x 800
Ask71.63 x 800
Day's Range70.83 - 72.08
52 Week Range66.88 - 102.00
Volume184,779
Avg. Volume519,836
Market Cap4.778B
Beta (5Y Monthly)0.27
PE Ratio (TTM)N/A
EPS (TTM)-1.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est118.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
118% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for QDEL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • QuidelOrtho Corporation
    QDEL: Raising target price to $68.00QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $68.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Business Wire

    QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA

    SAN DIEGO, September 21, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance t

  • Insider Monkey

    Should You Add QuidelOrtho (QDEL) to Your Portfolio?

    ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” second quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy outperformed the Russell 2000 value Index in the second quarter. On an absolute basis, the strategy gained all 11 sectors it invested in during the quarter. IT […]

  • Business Wire

    QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

    SAN DIEGO, August 28, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023.

Advertisement
Advertisement